TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial.

Loice Achieng Ombajo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.